New EFPIA leadership targets a collaborative approach to address Europe’s health challenges
At today’s EFPIA General Assembly in Brussels, Jean-Christophe Tellier, CEO and Chairman of the Executive Committee of UCB was elected as EFPIA President for the next two years. Speaking about his appointment Mr Tellier said “I am honored to be leading EFPIA at a time of great change, challenge and opportunity for Europe. I believe that by putting the patient at the forefront of decision making, and by connecting actors across the research community and health systems, we can realize the potential of the rapidly advancing science. Together, we can transform the lives of patients and continue to evolve how we manage our healthcare. Our industry is committed to playing its role as a partner in the fight against disease across Europe.”
Hubertus von Baumbach, Chairman of the Board of Managing Directors of Boehringer Ingelheim, was elected as First Vice-President at the General Assembly. He underlined that “ fostering medical innovation will be key to meet the challenges that patients and health systems in Europe are facing. We need a strong and reliable framework to strengthen Europe’s competitiveness and to be able to continue discovering, developing and delivering medical innovation that patients rely on. To achieve that, we stand ready to work with all stakeholders across the life sciences sector, regulators and healthcare providers to create an environment that makes Europe a world-leader in medical research and development”.
At the same meeting, David Meek, CEO of Ipsen, was elected as Vice President for the same term. Meek underlined the importance of patient access to new medicines, commenting that: “As our industry continues to bring forward new treatments for patients, EFPIA, along with all those involved in healthcare, share the goal of patients’ access to these new innovative treatments. As an industry we are committed to working with governments and healthcare systems to find ways to ensure patients get timely access to the treatments they need and deserve.”
Nathalie Moll, Director General of EFPIA said. “We are looking forward to working with the new EFPIA leadership at the beginning of a new EU Mandate. Our industry has a critical role to play in the fight against disease in Europe, by developing new treatments for patients, by working across healthcare to manage the introduction of those treatments and as an integral part of the growth of the European economy.”
Notes to Editors
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.